Biomarin Pharmaceutical (BMRN) Leases: 2010-2024
Historic Leases for Biomarin Pharmaceutical (BMRN) over the last 4 years, with Dec 2024 value amounting to $28.7 million.
- Biomarin Pharmaceutical's Leases fell 32.88% to $28.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $28.7 million, marking a year-over-year decrease of 32.88%. This contributed to the annual value of $28.7 million for FY2024, which is 32.88% down from last year.
- As of Q4 2024, Biomarin Pharmaceutical's Leases stood at $28.7 million, which was down 32.88% from $42.7 million recorded in Q4 2023.
- In the past 5 years, Biomarin Pharmaceutical's Leases registered a high of $49.1 million during Q1 2020, and its lowest value of $28.7 million during Q4 2024.
- Its 3-year average for Leases is $35.4 million, with a median of $34.9 million in 2022.
- In the last 5 years, Biomarin Pharmaceutical's Leases climbed by 22.32% in 2023 and then slumped by 32.88% in 2024.
- Biomarin Pharmaceutical's Leases (Quarterly) stood at $46.0 million in 2020, then declined by 16.99% to $38.2 million in 2021, then decreased by 8.54% to $34.9 million in 2022, then increased by 22.32% to $42.7 million in 2023, then tumbled by 32.88% to $28.7 million in 2024.
- Its Leases was $28.7 million in Q4 2024, compared to $42.7 million in Q4 2023 and $34.9 million in Q4 2022.